Aprameya Enginee

Why is Aprameya Engineering Ltd falling/rising?

As of 26-Jun, Aprameya Engineering Ltd's stock price is at 151.00, reflecting a significant decline of 52.15% year-to-date, underperforming against the Sensex. The stock is consistently trading below key moving averages, indicating a persistent downward trend despite increased investor participation.

As of 26-Jun, Aprameya Engineering Ltd's stock price is falling, currently at 151.00, which reflects a decrease of 1.75 (-1.15%). The stock has underperformed significantly over various periods, with a 1-week decline of 5.74% compared to a minor drop of 0.46% in the Sensex. Over the past month, the stock has decreased by 15.34%, while the Sensex has shown a slight increase of 0.10%. Year-to-date, Aprameya Engineering Ltd has experienced a substantial decline of 52.15%, in contrast to the Sensex's decrease of 7.94%. <BR><BR>Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a consistent downward trend. Although there has been a notable increase in investor participation, with a delivery volume rise of 124.36% against the 5-day average, this has not translated into a positive price movement. Overall, the combination of poor performance relative to the market benchmarks and the stock trading below key moving averages contributes to the ongoing decline in Aprameya Engineering Ltd's stock price.

Which are the latest news on Aprameya Enginee?

What does Aprameya Enginee do?

Aprameya Engineering Ltd is a micro-cap company in the hospital industry, incorporated as a Private Limited Company in December 2021. It currently has no available sales or profit data, with a market cap of INR 299 Cr and a P/E ratio of 60.00.

Overview:<BR>Aprameya Engineering Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was originally established as a Partnership Firm on September 5, 2003, and was registered on August 13, 2004, in Ahmedabad. It was subsequently incorporated as a Private Limited Company on December 28, 2021, following the conversion of the Partnership Firm. There is no sales or profit data available for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 299 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 60.00<BR>Industry P/E: 60<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.02<BR>Return on Equity: 7.27%<BR>Price-to-Book: 4.34<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Aprameya Enginee?

As of 10th June, Aprameya Engineering Ltd has a market capitalization of 299.00 Cr, classifying it as a Micro Cap company. There is no valid financial data available for the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Aprameya Engineering Ltd has a market capitalization of 299.00 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 64.26 Cr and Total Assets valued at 143.44 Cr.

Who are the peers of the Aprameya Enginee?

Peers of Aprameya Enginee include GPT Healthcare, Unihealth Hosp, Chandan Healthca, and others. Aprameya Enginee has good management risk but below-average growth, with a 1-year return of -8.67%, while Unihealth Hosp leads with a 1-year return of 154.25%.

Peers: The peers of Aprameya Enginee are GPT Healthcare, Unihealth Hosp, Chandan Healthca, Lotus Eye Hospit, Vaidya Sane, Asarfi Hospital, Aashka Hospitals, and Abate As Indust.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare, while Average management risk is found at Unihealth Hosp, Chandan Healthca, Vaidya Sane, and Asarfi Hospital, and the rest. Good management risk is attributed to Aprameya Enginee, while Below Average management risk is noted at Lotus Eye Hospit, Aashka Hospitals, and Abate As Indust. Growth is Excellent at Unihealth Hosp and Chandan Healthca, while Below Average growth is seen at Aprameya Enginee, Lotus Eye Hospit, Aashka Hospitals, and Abate As Indust, and the rest. Good growth is present at Asarfi Hospital, while Average growth is noted at Vaidya Sane. Capital Structure is Excellent at GPT Healthcare and Unihealth Hosp, Good at Chandan Healthca, Aprameya Enginee, Lotus Eye Hospit, Vaidya Sane, Asarfi Hospital, and the rest, while Average capital structure is found at Aashka Hospitals and Abate As Indust.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Unihealth Hosp at 154.25%, while Aprameya Enginee has a 1-year return of -8.67%, which is significantly lower. The peer with the lowest 1-year return is GPT Healthcare at -2.82%. Additionally, peers with a negative six-month return include Aprameya Enginee, Vaidya Sane, and Chandan Healthca.

Is Aprameya Enginee technically bullish or bearish?

As of December 1, 2025, the trend is mildly bullish with supportive indicators like a bullish MACD and daily moving averages, but mixed signals from the monthly RSI and Dow Theory suggest caution.

As of 1 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly chart and bullish signals from the Bollinger Bands and daily moving averages. However, the monthly RSI indicates a bearish signal, which tempers the overall bullish outlook. The lack of clear trends in Dow Theory and OBV on both weekly and monthly time frames suggests caution. Overall, while there are bullish indicators, the mixed signals indicate a moderate strength in the bullish stance.

Is Aprameya Enginee overvalued or undervalued?

As of August 28, 2025, Aprameya Enginee is considered very expensive and overvalued with a PE ratio of 21.89, despite strong stock performance and a year-to-date return of 75.85%, especially when compared to its peers like Max Healthcare and Apollo Hospitals.

As of 28 August 2025, the valuation grade for Aprameya Enginee has moved from fair to very expensive. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 21.89, an EV to EBITDA ratio of 15.64, and a ROE of 25.09%. <BR><BR>In comparison to its peers, Aprameya Enginee's PE ratio is significantly lower than that of Max Healthcare at 93.61 and Apollo Hospitals at 70.56, both of which are also categorized as very expensive. The company's stock has shown strong performance, with a year-to-date return of 75.85%, contrasting sharply with the Sensex's return of only 3.62% during the same period. This suggests that while the stock has performed well, its current valuation does not justify the high price relative to its earnings potential.

Who are the top shareholders of the Aprameya Enginee?

The top shareholders of Aprameya Enginee include Saurabh Kishorbhai Bhatt with 36.24%, Hem Finlease Private Limited at 2.7%, and individual investors holding 20.81%. There are no pledged promoter holdings or mutual funds involved.

The top shareholders of Aprameya Enginee include the promoters, with Saurabh Kishorbhai Bhatt holding the highest stake at 36.24%. Additionally, Hem Finlease Private Limited is the largest public shareholder, owning 2.7%. The company also has some foreign institutional investors (FIIs) holding a combined 0.41%. Individual investors collectively own 20.81% of the shares. There are no pledged promoter holdings, and no mutual funds are currently involved.

How has been the historical performance of the Aprameya Enginee?

Aprameya Enginee's financial performance declined from March 2023 to March 2024, with net sales dropping from Rs 78.12 crore to Rs 65.16 crore and profit after tax decreasing from Rs 5.37 crore to Rs 3.46 crore, despite an increase in total assets. The company faced challenges in revenue generation and profitability, reflected in negative cash flow from operating activities.

Answer:<BR>The historical performance of Aprameya Enginee shows a decline in key financial metrics from March 2023 to March 2024.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2024, Aprameya Enginee reported net sales of Rs 65.16 crore, down from Rs 78.12 crore in the previous year. Total operating income mirrored this decline, remaining at Rs 65.16 crore. The company's total expenditure decreased to Rs 58.80 crore from Rs 68.67 crore, leading to an operating profit (PBDIT) of Rs 6.82 crore, down from Rs 9.66 crore. Profit before tax also fell to Rs 4.60 crore from Rs 7.48 crore, resulting in a profit after tax of Rs 3.46 crore compared to Rs 5.37 crore in the prior year. The earnings per share decreased from Rs 3.84 to Rs 2.47, reflecting a decline in profitability. On the balance sheet, total assets increased to Rs 75.23 crore from Rs 61.73 crore, driven by a rise in current assets, particularly sundry debtors, which grew to Rs 58.06 crore from Rs 41.80 crore. Total liabilities also rose to Rs 75.23 crore, up from Rs 61.73 crore, with total debt increasing significantly to Rs 42.05 crore from Rs 28.74 crore. Cash flow from operating activities remained negative at Rs -9.00 crore, though cash flow from financing activities improved to Rs 11.00 crore from Rs 13.00 crore. Overall, the financial performance indicates challenges in revenue generation and profitability despite growth in total assets.

When is the next results date for Aprameya Enginee?

No Upcoming Board Meetings

Has Aprameya Enginee declared dividend?

No Dividend History Available